Lungenklinik Hemer Deutscher Gemeinschafts-Diakonieverband GmbH
- Address
- lock Available on a paid plan
Thoracic Oncology and Clinical Cancer Research
The Lungenklinik Hemer Deutscher Gemeinschafts-Diakonieverband GmbH is conducting a strong portfolio of studies in neoplasms, centered on non-small cell lung cancer and small cell lung cancer. Research here focuses on testing new treatment combinations, improving outcomes for advanced disease, and refining perioperative and biomarker-guided care.
- Advanced and metastatic NSCLC, including biomarker-defined groups such as EGFR, ALK, KRAS G12C, HER2, and ROS1 variants
- Immunotherapy and combination strategies aimed at improving survival and disease control
- Studies in resectable and unresectable lung cancer to support better treatment planning around surgery and chemoradiation
- Evaluation of newer targeted and antibody-based therapies for previously treated or hard-to-treat lung cancers
Overall, this site contributes to advancing personalized care for lung cancer patients through trials designed to assess treatment effectiveness, safety, and the added value of newer therapeutic approaches.
Respiratory Tract Diseases and Pulmonary Fibrosis Research
Beyond oncology, the site also studies chronic respiratory tract diseases such as idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung diseases, and progressive pulmonary fibrosis. These trials aim to better understand lung function decline and explore treatments that may slow disease progression.
- Idiopathic pulmonary fibrosis and related fibrosing lung disorders
- Testing therapies intended to preserve lung function and reduce worsening fibrosis
- Research focused on long-term tolerability and ongoing disease management
This work broadens the site’s research profile by addressing serious non-cancer lung conditions that can greatly affect breathing, daily activity, and quality of life.
Diagnostic and Therapeutic Techniques in Lung Cancer Care
Several studies at the site examine analytical, diagnostic, and therapeutic techniques used in thoracic oncology, including biomarker-driven treatment selection and combined-modality approaches. The aim is to improve how clinicians identify the right therapy and measure benefit more precisely.
- Biomarker-guided treatment strategies in NSCLC
- Research on combining radiotherapy with systemic treatment to improve control of locally advanced disease
- Studies evaluating response, survival, and disease-free outcomes to support better treatment decisions
At Lungenklinik Hemer, this research helps connect modern diagnostics with more tailored treatment strategies for patients with complex lung diseases.
Asthma and Inflammatory Airway Disease
The site also includes trials in eosinophilic asthma, reflecting interest in inflammatory airway disease alongside its cancer-focused program. These studies are designed to evaluate whether newer add-on treatments can improve symptom control in patients who remain poorly controlled on standard therapy.
- Eosinophilic asthma with inadequate control on usual inhaled treatment
- Assessment of new biologic approaches to improve asthma management
- Focus on treatment effectiveness and safety in everyday respiratory care
This adds a broader respiratory medicine dimension to the site’s clinical research, supporting patients with both malignant and non-malignant lung conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 57 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 57 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 16 by active trials.
- 1AstraZeneca AB3active
lock +15 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Lungenklinik Hemer Deutscher Gemeinschafts-Diakonieverband GmbH
lock Showing 1 of 36 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Open-Label Study Comparing Sigvotatug Vedotin and Docetaxel in Adults with Previously Treated Non-Small Cell Lung Cancer | Seagen Inc. | Phase III | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 57 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 17 | Unknown | 2017-09-18 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.